Mylan CEO Bresch Admits "Full Responsibility" For EpiPen Price Hikes

Mylan CEO Heather Bresch arrived at the 2016 Forbes Healthcare Summit on December 1 surrounded by a cloud of fresh controversy, this one created by her mere appearance at the event. Bresch had refused to testify at a Congressional hearing the day before, where Senator Chuck Grassley (R-Iowa) had planned to review the $465 million settlement Mylan agreed to pay the U.S. Department of Justice over allegations it overcharged Medicaid for its allergy shot EpiPen. Grassley is crying foul that Bresch volunteered to speak at the summit but refused to defend Mylan’s actions before Congress.

Back to news